Found: 6
Select item for more details and to access through your institution.
Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese nonalcoholic fatty liver disease patients: a double-blind randomized placebocontrolled clinical trial.
- Published in:
- BMC Complementary & Alternative Medicine, 2019, v. 19, n. 1, p. 1, doi. 10.1186/s12906-019-2465-0
- By:
- Publication type:
- Article
Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial.
- Published in:
- Nutrition & Metabolism, 2019, v. 16, n. 1, p. N.PAG, doi. 10.1186/s12986-019-0331-1
- By:
- Publication type:
- Article
Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial.
- Published in:
- Nutrition & Metabolism, 2018, v. 15, n. 1, p. N.PAG, doi. 10.1186/s12986-018-0297-4
- By:
- Publication type:
- Article
The nanocurcumin reduces appetite in obese patients with non-alcoholic fatty liver disease (nafld): a double-blind randomized placebo-controlled clinical trial.
- Published in:
- Nanomedicine Journal, 2018, v. 5, n. 2, p. 67, doi. 10.22038/nmj.2018.005.003
- By:
- Publication type:
- Article
The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial.
- Published in:
- 2017
- By:
- Publication type:
- journal article